^
Association details:
| Biomarker: | Chr del(13q) + Chr del(11q) + SF3B1 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Zydelig (idelalisib) (PI3Kδ inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL
Published date:
11/06/2019
Excerpt:
...we profiled 6 primary human CLLs (4 carrying del[13q] and 2 carrying del[13q], [11q] and mutant SF3B1)...Notably, the 2 primary samples carrying del(13q)/(11q)-SF3B1 were more resistant to BCRi compared to those with del(13q), as evidenced by reduced BIM signals (p= 0.01, the Van Elteren test).
DOI:
https://doi.org/10.1182/blood-2019-127293
